The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 14, 2023

Filed:

Jan. 03, 2019
Applicant:

Dicerna Pharmaceuticals, Inc., Lexington, MA (US);

Inventor:

Shanthi Ganesh, Shrewsbury, MA (US);

Assignee:

DICERNA PHARMACEUTICALS, INC., Lexington, MA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07H 21/04 (2006.01); A61K 31/713 (2006.01); A61P 35/04 (2006.01); A61K 31/4245 (2006.01); C07K 16/28 (2006.01); C12N 9/02 (2006.01); C12N 15/113 (2010.01); C07K 14/47 (2006.01);
U.S. Cl.
CPC ...
A61K 31/713 (2013.01); A61K 31/4245 (2013.01); A61P 35/04 (2018.01); C07K 16/2818 (2013.01); C07K 16/2827 (2013.01); C12N 9/0069 (2013.01); C12N 15/113 (2013.01); C07K 14/47 (2013.01); C12N 2310/14 (2013.01); C12N 2320/31 (2013.01); C12Y 113/11052 (2013.01);
Abstract

Provided herein are methods and compositions for treating cancer, including cancer that is not responsive to immunotherapy. In one aspect, the methods of treatment comprise administering to the subject a therapeutically effective amount of a β-catenin inhibitor, a therapeutically effective amount of an IDO inhibitor, and a therapeutically effective amount of an immunotherapeutic agent. Another aspect is directed to pharmaceutical compositions comprising a β-catenin inhibitor for use in treating cancer, wherein the composition is administered in combination with an IDO inhibitor and an immunotherapeutic agent. Yet another aspect is directed to a method of potentiating the therapeutic effect of immunotherapy against a cancer using a β-catenin inhibitor, such as a β-catenin nucleic acid inhibitor molecule, in combination with an IDO inhibitor.


Find Patent Forward Citations

Loading…